The useful answer starts with appetite
Semaglutide helps people lose weight primarily by changing the regulation of appetite and food intake. It activates the receptor for GLP-1, a hormone involved in that regulation. That is more useful than describing it as a medicine that simply burns fat. I would separate three questions when reading a claim: what the drug does biologically, what a study measured and what you should expect personally. Those questions need different evidence. Understanding the mechanism can explain the treatment approach, but it cannot provide your individual outcome or tell you which telehealth company is best.[1]
What a human appetite study tested
A randomized study enrolled 72 adults with obesity and compared weekly semaglutide 2.4 mg with placebo over 20 weeks. Researchers assessed appetite, eating control, food cravings and energy intake at a meal where participants could choose how much to eat. This is a direct look at eating behavior rather than a theory inferred from weight loss alone. The setting matters: a measured laboratory meal is a controlled observation. It does not reproduce every meal, every stressor or every nutritional decision in a person’s daily life.[2]
Read the 35% result in its actual setting
At week 20, energy intake at the freely chosen lunch was 35% lower in the semaglutide group than the placebo group. Appetite and eating-control measures also favored semaglutide. I would keep the phrase “at the measured lunch” beside that percentage. It is not proof that everyone should eat 35% less each day, nor a prescription for a calorie deficit. A result can explain how a treatment works without becoming a target. The table below separates the observed outcomes from conclusions the study did not establish.[2]
| Finding at week 20 | How to read it |
|---|---|
| 72 adults with obesity; semaglutide versus placebo | A small mechanistic trial, not the entire clinical evidence base |
| 35% lower energy intake at the measured lunch | A controlled meal result, not a daily calorie prescription |
| Improved appetite, eating-control and craving measures | Supports an appetite-related explanation |
| No detected gastric-emptying delay by paracetamol testing | Specific method and time point; not proof of no gastric effect |
Once-weekly semaglutide 2.4 mg over 20 weeks. Do not turn a group-level laboratory finding into an individual nutrition target. Source: Friedrichsen et al.: semaglutide appetite and energy-intake trial.
Why stomach emptying is only part of the story
Semaglutide can delay stomach emptying, but “food stays in your stomach longer” is an incomplete explanation of weight loss. The same mechanistic trial did not detect delayed gastric emptying at week 20 using its paracetamol-absorption assessment. That finding is limited by the measurement method and does not cancel the product-label warning about gastric emptying. It does show why a simple diagram of a full stomach cannot carry the whole explanation. Appetite regulation and observed eating behavior deserve their own space in the discussion.[2]
The glucose effect answers another question
Semaglutide also affects insulin and glucagon secretion in a glucose-dependent manner. That helps explain its role in diabetes care. It does not mean appetite, blood glucose and weight are interchangeable measures of whether treatment is working. If your reason for treatment includes diabetes, ask which glucose measures your clinician intends to follow. If your question is weight management, discuss the relevant outcomes and nutritional needs instead of borrowing a diabetes result as a weight-loss prediction. Keep the prescribed product and treatment goal in the same conversation.[1]
Longer weight-loss trials measure something different
STEP 1 followed 1,961 adults without diabetes for 68 weeks. Average weight change was −14.9% with semaglutide 2.4 mg and −2.4% with placebo, both alongside lifestyle intervention. That longer trial measured a weight outcome; the appetite study explored part of the explanation. Neither average tells you exactly what will happen in your first month. When people combine a mechanism diagram with a dramatic before-and-after promise, I would ask which population and follow-up period support the promise. A biological explanation is not an outcome guarantee.[3] Explore how to read GLP-1 research for more detail. Explore the plateau evidence for more detail.
Less hunger still needs a workable care plan
A useful follow-up question is how to maintain adequate nutrition and communicate troublesome symptoms while appetite changes. Bring the exact product, current dose, recent symptoms and questions about food intake to your care team. Do not judge success by how little you can tolerate eating. Likewise, absence of nausea does not prove absence of drug action, and severe symptoms are not a badge of effectiveness. Our side-effect explainers can help you understand reported trial rates; the clinician’s job is to assess your circumstances and decide what needs attention. Common gastrointestinal adverse reactions include nausea, vomiting, diarrhea and constipation. Semaglutide products also carry a boxed warning about thyroid C-cell tumors observed in rodents; human relevance is unknown. A personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. These limits belong in the treatment discussion alongside the potential benefits.[4] Explore nausea trial rates for more detail.
The medicine and the service need separate comparisons
The mechanism belongs to the medication evidence. An online service adds prescribing arrangements, follow-up access, insurance assistance and a payment contract. I would assess those details independently. A company does not acquire the trial’s average result simply by advertising semaglutide access. If you are comparing services, ask who answers clinical questions and what the full quote includes. Our Found review illustrates the distinction between a care membership and a separate medication budget. Use it to examine a service model, then discuss treatment choices with a qualified clinician. Explore the Found service review for more detail. Explore the provider checklist for more detail.
Put the questions to work
Compare our researched providers or build your provider checklist.
Explore relevant provider reviews
Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.
Continue your research
Sources & scope
Sources checked October 14, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- Wegovy US prescribing information, revised June 2026
- Friedrichsen et al.: semaglutide appetite and energy-intake trial
- Wilding et al.: STEP 1 trial
- Ozempic US prescribing information, contraindications and adverse reactions
Prices and terms can change. Confirm your specific offer directly with the provider.